Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Gallbladder Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 61Cisplatin 39Oxaliplatin 31Capecitabine 29Fluorouracil 22Leucovorin 20Irinotecan 12pembrolizumab 11130-nm albumin-bound paclitaxel 10durvalumab 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Taxes 6Platinum 6Magnetic Resonance Spectroscopy 6Biopsy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Specimen Handling 5Sorafenib 5Radiotherapy 5Docetaxel 5Carboplatin 5Immunohistochemistry 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Watchful Waiting 3Tegafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × MK 2206 × Gastrointestinal × Clear all
NCT01425879 2016-06-17

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
8 enrolled 8 charts
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡